Allink生物疗法为Lanchi公司领导的癌症和免疫疾病抗体疗法筹集了42M美元。 Allink Biotherapeutics raises $42M for cancer and immune disease antibody therapies, led by Lanchi Ventures.

Allink生物治疗公司是一家生物技术公司,侧重于癌症和免疫疾病高级抗体疗法,在由Lanchi公司牵头的A系列资金回合中筹集了4 200万美元。 Allink Biotherapeutics, a biotech firm focused on advanced antibody therapies for cancer and immune diseases, has raised $42 million in a Series A funding round led by Lanchi Ventures. 该基金将支持全球第一/二阶段对其主要候选人的临床试验,并扩大技术平台和国际存在。 The funds will support global Phase I/II clinical trials for its lead candidates and expand its technology platform and international presence. 投资包括数家风险资本公司的参与。 The investment includes participation from several venture capital firms.